Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Primary Target

T cell mediated immunity

40

Histamine H1 receptor

316

Dopamine D2 receptor

311

DNA

282

Serotonin 2a (5-HT2a) receptor

237

All Match

Any Match

Exclude Selected

Exclude Selected

Development Status

US Approved OTC

38

Possibly Marketed Outside US

2

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

40

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1921

38

2013

1

Unknown

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Acute myeloid leukemia

38

Breast cancer

38

Caries

38

Diaper dermatitis

38

Dysgeusia

38

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

40

Preventing

38

Secondary

38

Diagnostic

1

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

38

CNS Penetrant

1

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Smithson, R.

38

Eli Lilly

1

Photogen Technologies

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

38

Mixture

1

Protein

1

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

FDA UNII

40

CAS

39

PUBCHEM

39

EPA CompTox

37

RXCUI

26

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ALIMENTARY TRACT AND METABOLISM

3

BLOOD AND BLOOD FORMING ORGANS

1

DERMATOLOGICALS

1

SENSORY ORGANS

1

VARIOUS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

MINERAL SUPPLEMENTS

2

ALL OTHER THERAPEUTIC PRODUCTS

1

BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS

1

MEDICATED DRESSINGS

1

OPHTHALMOLOGICALS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

OTHER MINERAL SUPPLEMENTS

2

ALL OTHER THERAPEUTIC PRODUCTS

1

DIAGNOSTIC AGENTS

1

I.V. SOLUTION ADDITIVES

1

MEDICATED DRESSINGS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Zinc

2

Colouring agents

1

Detoxifying agents for antineoplastic treatment

1

Electrolyte solutions

1

Various alimentary tract and metabolism products

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

37

Principal Form

3

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 10 of 40 results

First page disabled
Previous page disabled
1
Next page
Next page

ZINC CATION

13S1S8SF37

Export Data
Search for Structure

Status:

US Approved OTC

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

respiratory burst

Streptococcus mutans

transformed cell apoptotic process

ultraviolet B-induced damage

T cell mediated immunity

Zinc transporter ZIP1

Zinc transporter ZIP2

Conditions:

Renal insufficiency

Ulcerative colitis

Acute myeloid leukemia

Zinc deficiency

Poison Ivy dermatitis

Diaper dermatitis

Gastrointestinal disorders

There is no available information related any biological and pharmaceutical application of ammonium tetrachlorozincate.

ROSE BENGAL SODIUM

956575SN5L

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

First approved in 2013

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

HSV-1, McKrae strain

Dendritic cells

UDP-glucuronosyltransferase 1-6

Protein translocase subunit SecA

Cytochrome P450 3A4/3A5

T cell mediated immunity

Conditions:

Herpes simplex keratitis

Atopic dermatitis

Rose bengal sodium (RB) is a small molecule, halogenated xanthene being developed by Provectus Biopharmaceuticals (formerly Provectus Pharmaceuticals). It is commonly used in eye drops to stain damaged conjunctival and corneal cells and thereby ident...

ify damage to the eye. The stain is also used in the preparation of Foraminifera for microscopic analysis, allowing the distinction between forms that were alive or dead at the time of collection. A form of rose bengal is also being studied as a treatment for certain cancers and skin conditions. The cancer formulation of the drug, known as PV-10, is currently undergoing clinical trials for melanoma and breast cancer. Recently, interest in RB as a therapeutic cancer treatment has increased due to significant anti-tumor responses with direct tumor injection in human clinical trials for metastatic melanoma. In these patients, there has been the implication that RB may mount a T-cell mediated anti-tumor response and impart antigen-specific responses in distant bystander lesions.

FRENTIZOLE

7EY946394I

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Aβ-ABAD/HSD17B10 interaction

T cell mediated immunity

Conditions:

Rheumatoid arthritis

Systemic lupus erythematosus

Frentizole, a nontoxic antiviral and immunosuppressive agent, was used clinically in rheumatoid arthritis and systemic lupus erythematosus. Frentizole was more effective in suppressing human lymphocytes responding to Con A and PWM, than it was in cel...

ls activated by PHA, specific antigen, or alloantigen. Methylprednisolone, on the other hand, was more inhibitory for cells stimulated by PHA, specific antigen, or alloantigen. Frentizole, even at super immunosuppressive doses, does not predispose the hose (mice) to Pseudomonas aeruginosa, Candida albicans, herpes simplex virus, or Ann Arbor influenza virus. Frentizole is an inhibitor of the Aβ-ABAD interaction.

ZINC DIBUTYRATE

VA6XH8E3JX

Export Data
Search for Structure

Status:

US Approved OTC

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

respiratory burst

Streptococcus mutans

transformed cell apoptotic process

ultraviolet B-induced damage

T cell mediated immunity

Zinc transporter ZIP1

Zinc transporter ZIP2

Conditions:

Renal insufficiency

Ulcerative colitis

Acute myeloid leukemia

Zinc deficiency

Poison Ivy dermatitis

Diaper dermatitis

Gastrointestinal disorders

There is no available information related any biological and pharmaceutical application of ammonium tetrachlorozincate.

ZINC CITRATE DIHYDRATE

021IBV57IL

Export Data
Search for Structure

Status:

US Approved OTC

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

respiratory burst

Streptococcus mutans

transformed cell apoptotic process

ultraviolet B-induced damage

T cell mediated immunity

Zinc transporter ZIP1

Zinc transporter ZIP2

Conditions:

Renal insufficiency

Ulcerative colitis

Acute myeloid leukemia

Zinc deficiency

Poison Ivy dermatitis

Diaper dermatitis

Gastrointestinal disorders

There is no available information related any biological and pharmaceutical application of ammonium tetrachlorozincate.

ZINC SUCCINATE

IY01B595GR

Export Data
Search for Structure

Status:

US Approved OTC

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

respiratory burst

Streptococcus mutans

transformed cell apoptotic process

ultraviolet B-induced damage

T cell mediated immunity

Zinc transporter ZIP1

Zinc transporter ZIP2

Conditions:

Renal insufficiency

Ulcerative colitis

Acute myeloid leukemia

Zinc deficiency

Poison Ivy dermatitis

Diaper dermatitis

Gastrointestinal disorders

There is no available information related any biological and pharmaceutical application of ammonium tetrachlorozincate.

ZINC OROTATE DIHYDRATE

2R18GO895S

Export Data
Search for Structure

Status:

US Approved OTC

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

respiratory burst

Streptococcus mutans

transformed cell apoptotic process

ultraviolet B-induced damage

T cell mediated immunity

Zinc transporter ZIP1

Zinc transporter ZIP2

Conditions:

Renal insufficiency

Ulcerative colitis

Acute myeloid leukemia

Zinc deficiency

Poison Ivy dermatitis

Diaper dermatitis

Gastrointestinal disorders

There is no available information related any biological and pharmaceutical application of ammonium tetrachlorozincate.

ZINC MONOCARBONATE

K8290PTQ4F

Export Data
Search for Structure

Status:

US Approved OTC

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

respiratory burst

Streptococcus mutans

transformed cell apoptotic process

ultraviolet B-induced damage

T cell mediated immunity

Zinc transporter ZIP1

Zinc transporter ZIP2

Conditions:

Renal insufficiency

Ulcerative colitis

Acute myeloid leukemia

Zinc deficiency

Poison Ivy dermatitis

Diaper dermatitis

Gastrointestinal disorders

There is no available information related any biological and pharmaceutical application of ammonium tetrachlorozincate.

ZINC NITRIDE

7OOJ6UE14L

Export Data
Search for Structure

Status:

US Approved OTC

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

respiratory burst

Streptococcus mutans

transformed cell apoptotic process

ultraviolet B-induced damage

T cell mediated immunity

Zinc transporter ZIP1

Zinc transporter ZIP2

Conditions:

Renal insufficiency

Ulcerative colitis

Acute myeloid leukemia

Zinc deficiency

Poison Ivy dermatitis

Diaper dermatitis

Gastrointestinal disorders

There is no available information related any biological and pharmaceutical application of ammonium tetrachlorozincate.

AMMONIUM PENTACHLOROZINCATE

3ILV18PW3Y

Export Data
Search for Structure

Status:

US Approved OTC

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

respiratory burst

Streptococcus mutans

transformed cell apoptotic process

ultraviolet B-induced damage

T cell mediated immunity

Zinc transporter ZIP1

Zinc transporter ZIP2

Conditions:

Renal insufficiency

Ulcerative colitis

Acute myeloid leukemia

Zinc deficiency

Poison Ivy dermatitis

Diaper dermatitis

Gastrointestinal disorders

There is no available information related any biological and pharmaceutical application of ammonium tetrachlorozincate.

Showing 1 - 10 of 40 results

First page disabled
Previous page disabled
1
Next page
Next page

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1